Rizatriptan (Rizamelt) dispersible tab 10 mg: Supply issue
Due to an issue at the factory, there was a supply issue affecting Rizamelt tablets (Pharmacode: 2394634).
On this page
Affected product
Due to an issue at the factory, the supplier will run out of the following product:
- Chemical: Rizatriptan
- Presentation: Tab orodispersible 10 mg
- Brand: Rizamelt
- Pharmacode: 2394634
- Subsidy: $4.84
- Measure / Qty: per 30
People who use Rizamelt
If your usual Rizamelt tablets are not available, your pharmacist can dispense Rizatriptan Rising tablets. They work the same way and contain the same amount of active ingredients.
Medsafe has not had an opportunity to review this product. However, it is approved for use in other countries. Your prescriber will discuss this with you before they prescribe it. You can read more information about unapproved medicine on the Healthify website.
Unapproved medicines | Healthify.nz(external link)
Alternative product listed 12 June
We have funded an alternative from 12 June 2026. It is not Medsafe approved and will need to be prescribed and dispensed in line with section 29A of the Medicines Act. Note the pack size differs from Rizamelt.
- Presentation: Tab orodispersible 10 mg
- Brand: Rizatriptan Rising
- Pharmacode: 2733145
- Subsidy: $2.46
- Measure / Qty: per 18
This listing will not appear in the Online Schedule until it is updated for 1 July 2026. It will appear automatically in RxOne, ScriptSense, and Toniq from 12 June.
This product should be available for wholesalers to order from Orspec by the end of June.
How to claim:
The Sector Operations Group will be able to process claims for June dispensing of the new Pharmacode.
Prescribing and supplying an unapproved medicine
Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people when there is supply issue affecting the registered brand.
We know supplying an unapproved medicine is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment.
We apologise for any inconvenience this causes.
What patients need to know about unapproved medicines – Healthify website(external link)
Supply issue flyers for pharmacists
- General Supply Issue A5 Flier [PDF 111 KB]
- Unapproved Medicine flier A5 [PDF 131 KB]
Resupply
The supplier expects Rizamelt to be available again in November 2026.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)